Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(0)
•••
Comment by WatchLearnEarnon Apr 17, 2018 2:43am
210 Views
Post# 27895477

RE:RE:RE:RE:RE:RE:RE:example

RE:RE:RE:RE:RE:RE:RE:example I love it when someone posts a level-headed and reasonable post and it gets 1-starred by some idiot(s) who only want to hear ecstatic cheers, fluff and pie-in-the-sky predictions about billion dollar valuations.

Sometimes the 1-star posts are the best ones. Case in point right here...


 
HossBender wrote: The upfront payment would be nowhere near the milestone payments. Pharmaceutical companies are all about reducing risk, the reason the upfront payment was not disclosed is likely because it was not significant in comparison to the $300 some million in potential milestone payments. Add on the possibility of royalties and you may have the potential for billions, however this would not be achieved until several years in the future and only if they meet the milestones and get the drug(s) to market!
 
I think that the deal that Kineta received would be similar (in structure) to a deal that Antibe could potentially see in the future, I mean I'd rather see an outright buyout but those types of deals are few and far between. 


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities